ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the tr…
Biotechnology
US, San Diego [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared ACADIA Pharmaceuticals Inc. (ACAD) to it's peer group, including competitors as well as it's industry.
All monetary values in mil. except volume - volume is in thousands.
Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biotechnology Average | - - | - - | - - | 38,903.06 | 13,479.74 | 621.35 | 434.51 | -1,110.10 | 0.00 | 11.2560 | 44.01 | -0.8541 | -20.5924 | -0.08 | -0.10 | 6.7303 | - - | ||
Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 701.8537 | 2,849.43 | 3.0051 | 85.3485 | 0.15 | 8.35 | 61.5621 | - - | ||
Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
Reata Pharmaceuticals, Inc. RETA | 172.36 | 0.04 0.02% | 1,909 vs. 954 | 6,566.00 | 22.00 | 192.00 | -70.00 | -1,490.00 | 5.1200 | 5.4820 | 0.0000 | 0.9628 | 8.4849 | 2.2110 | 0.3840 | 2.8209 | 38.00 | ||
Sarepta Therapeutics, Inc. SRPT | 114.23 | 3.73 3.38% | 872 vs. 866 | 10,911.00 | 413.00 | 36.00 | -284.00 | -4,410.00 | 0.3800 | 83.5325 | 0.0000 | 0.8777 | 0.0874 | 0.0376 | 0.0112 | 2.9737 | 95.00 | ||
PTC Therapeutics, Inc. PTCT | 43.23 | 0.34 0.79% | 534 vs. 718 | 3,334.00 | 210.00 | -91.00 | 6.00 | -3,375.00 | -1.2000 | -5.9705 | 0.0000 | 0.6846 | -0.4358 | 0.1024 | -0.0512 | 1.8854 | 77.00 | ||
ACADIA Pharmaceuticals Inc. ACAD | 16.37 | 0.19 1.17% | 1,398 vs. 1,353 | 2,723.00 | 205.00 | 16.00 | 29.00 | -2,414.00 | 0.1000 | 45.4426 | 0.0000 | 0.8885 | 0.0804 | 0.0357 | 0.0194 | 1.7260 | 166.00 | ||
Madrigal Pharmaceuticals, Inc. MDGL | 347.45 | 18.21 5.53% | 532 vs. 380 | 7,578.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.0000 | 0.0000 | 0.0000 | -0.1734 | -0.1363 | 9.2623 | 21.00 | ||
Akero Therapeutics, Inc. AKRO | 32.73 | 1.53 4.90% | 824 vs. 549 | 2,284.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
Blueprint Medicines Corporation BPMC | 94.15 | -2.47 -2.56% | 663 vs. 628 | 5,980.00 | 96.00 | 89.00 | -102.00 | -2,250.00 | 1.4500 | 16.6530 | 0.0000 | 0.9168 | 0.9274 | 0.2869 | 0.0858 | 3.4266 | 63.00 | ||
Krystal Biotech, Inc. KRYS | 190.40 | 8.11 4.45% | 222 vs. 226 | 5,475.00 | 45.00 | 0.00 | 14.00 | -268.00 | 0.0300 | 1336.3467 | 0.0000 | 0.9465 | 0.0206 | 0.0012 | 0.0011 | 12.2870 | 28.00 |
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.